APRAMEYA2025-10-012026-03-31APRAMEYA2026-03-31APRAMEYA2025-03-31APRAMEYA2025-04-012026-03-31APRAMEYA2025-10-012026-03-31in-capmkt:OtherExpenses1MemberAPRAMEYA2025-10-012026-03-31in-capmkt:OtherExpenses2MemberAPRAMEYA2025-04-012026-03-31in-capmkt:OtherExpenses1MemberAPRAMEYA2025-04-012026-03-31in-capmkt:OtherExpenses2MemberAPRAMEYA2026-03-31OtherNoncurrentFinancialAssetsDomain1APRAMEYA2026-03-31OtherNoncurrentAssetsDomain1APRAMEYA2026-03-31OtherNoncurrentAssetsDomain2APRAMEYA2026-03-31OtherCurrentFinancialAssetsDomain1APRAMEYA2026-03-31OtherCurrentAssetsDomain1APRAMEYA2026-03-31OtherNoncurrentFinancialLiabilitiesDomain1APRAMEYA2026-03-31OtherCurrentFinancialLiabilitiesDomain1APRAMEYA2026-03-31OtherCurrentLiabilitiesDomain1APRAMEYA2025-10-012026-03-31in-capmkt:ReportableSegments1MemberAPRAMEYA2025-10-012026-03-31in-capmkt:ReportableSegments2MemberAPRAMEYA2025-04-012026-03-31in-capmkt:ReportableSegments1MemberAPRAMEYA2025-04-012026-03-31in-capmkt:ReportableSegments2MemberAPRAMEYA2025-10-012026-03-31in-capmkt:ReportableSegments1MemberAPRAMEYA2025-10-012026-03-31in-capmkt:ReportableSegments2MemberAPRAMEYA2025-04-012026-03-31in-capmkt:ReportableSegments1MemberAPRAMEYA2025-04-012026-03-31in-capmkt:ReportableSegments2MemberAPRAMEYA2025-10-012026-03-31in-capmkt:ReportableSegments1MemberAPRAMEYA2026-03-31in-capmkt:ReportableSegments1MemberAPRAMEYA2025-10-012026-03-31in-capmkt:ReportableSegments2MemberAPRAMEYA2026-03-31in-capmkt:ReportableSegments2MemberAPRAMEYA2025-10-012026-03-31in-capmkt:ReportableSegments1MemberAPRAMEYA2026-03-31in-capmkt:ReportableSegments1MemberAPRAMEYA2025-10-012026-03-31in-capmkt:ReportableSegments2MemberAPRAMEYA2026-03-31in-capmkt:ReportableSegments2MemberAPRAMEYA2025-10-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss1APRAMEYA2025-04-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss1APRAMEYA2025-10-012026-03-31AuditorDomain1iso4217:INRiso4217:INRxbrli:shares000000APRAMEYANOTLISTEDINE0LQG01010APRAMEYA ENGINEERING LIMITEDSMEEquity2025-04-012026-03-312026-05-282026-05-13INRLakhsHalf YearlyYearlyMulti segment2026-05-2813:00:002026-05-2816:00:00trueCash Flow IndirectDeclaration of unmodified opinion2025-10-012026-03-31AuditedConsolidated129916000293200013284800001813500017785000195260001610400047000079302000151322000-184740000-18474000199000-2346000-21470000-163270000000-16327000473000-15854000-16588000261000-1615000026100019040000010-0.87-0.8700-0.87-0.87Notes: <BR> 1 The above audited consolidated financial results have been duly audited by statutory auditors, recommended by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on 28th May, 2026. These consolidated financial results are prepared in accordance with the principles laid down in lndian Accounting Standards (lnd AS) as prescribed under Section 133 of the companies Act, 2013, ("the Act") read with the relevant Rules thereunder and other accounting principles generally accepted in lndia. <BR> <BR> 2 There are two major Business segments. One is trading of Medical Equipment's(Trading Sales) and another is supplies for Infra Projects for health care sectors(Turnkey project supplies). Refer Annexure "A" Segment Reporting. <BR> <BR> 3 The Government of India has notified the implementation of four new Labour Codes effective 21st November, 2025, by consolidating and rationalizing 29 existing labour laws. Further based on management estimates and actuarial valuation obtained, the company has considered the impact of gratuity liability arising from the implementation of the New Labour Codes and accordingly the financial impact of the same has been recognized as an additional expense of Rs. 11.38 Lakhs in the financial results for the Half year ended 31st March, 2026. <BR> <BR> 4 During the half year , the company has incorporated a subsidiary Company namely M/s Aprameya Medtech Private Limited on 04th October, 2025. The company has made investment by way of subscription to 3,50,000 Equity Shares of Rs. 10/- each aggregating to Rs. 35.00 Lakhs. Accordingly, the Company shall hold 70% of the Shareholding of a subsidiary company "Aprameya Medtech Private Limited". In view of above, the consolidated financial statements have been prepared for the first time during the half year ended on 31st March 2026. <BR> <BR> 5 The figures in respect of results for the half year ended March31, 2026 are the balancing figures between the audited figures in respect of the full financial year and published half yearly figures upto September 30, 2025 <BR> 2025-04-012026-03-31AuditedConsolidated55131400048770005561910000740860004489100033658000364340009270002933250004833210007287000007287000025899000-431000021589000051281000000051281000359000516400005102000026100051380000261000190400000105035910002.682.68002.682.68Other Expenses47422000Turnkey project Expenses31880000Other Expenses106845000Turnkey project Expenses1864800001277300007410000413000000000468200004682000093780001959200089717000268610000555198000315700055751000850001543000062962100014282000622010007329650000082268200019040000050359100069399100017610006957520001792300000056200018485000347700000219620005343700066320002501400031646000414100089224000131990002252000293000010496800000126930000822682000Other financial assets46820000Other non-current assets17811000Non-current tax assets1781000Other financial assets15430000Other current assets62201000Other non-current financial liabilities562000Other financial liabilities4141000Other current liabilities13199000Trading Sales57246000Turnkey project supply72670000Trading Sales106060000Turnkey project supply445254000129916000551314000129916000551314000Trading Sales22989000Turnkey project supply32017000Trading Sales31288000Turnkey project supply2026370005500600023392500073480000161055000-1847400072870000Trading Sales75158000Turnkey project supply65409000072924800093434000822682000Trading Sales10402000Turnkey project supply2572200036124000194470005557100030998000448910006198740000006054000-3210000-3710710000-3809000009270000161700000-33220000004847000000000030126300037413300000061800000031233300000000000095250000001000000000000000000048470000-39745000-445230001500000000000028500000260574000003599000000-26656400012460000124600019110003157000Remeasurement of the defined benefit plan632000632000Remeasurement of the defined benefit plan48000048000015900012100000473000359000AuditedtrueCNK AND ASSOCIATES LLPtrue2027-07-31